NIH Public Access

Author Manuscript

J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2013 April 15.

Published in final edited form as:

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 April 15; 893-894: 34–42. doi:10.1016/j.jchromb. 2012.02.029.

LC/LC-MS/MS of an Innovative Prostate Human Epithelial Cancer (PHEC) *in vitro* Model System

John D. Lapek Jr.¹, James L. McGrath², William A. Ricke³, and Alan E. Friedman^{1,*}

¹Department of Environmental Medicine, University of Rochester Medical Center

²Department of Biomedical Engineering, University of Rochester Medical Center

³Department of Urology, University of Rochester Medical Center

Abstract

This work describes the proteomic characterization of a novel *in vitro* prostate cancer model system, the clonal Prostatic Human Epithelial Cancer (PHEC) cell lines. The model is composed of three cell lines representing the three progressive cancer states found *in vivo*: non-tumorigenic, tumorigenic, and metastatic. The cell lines were evaluated for differential protein expression between states using two dimensional liquid:liquid chromatographic separation followed by mass spectral identification. The proteins from cellular extracts were first separated using liquid:liquid primary separation based on their isoelectric points and molecular masses. The resulting peptide fractions were applied to liquid chromatography mass spectrometry (LCMS) separation for mass determination and protein identification based on Mascot database inquiry. Over 200 proteins that change expression over the course of progression of this *in vitro* prostate cancer model were discovered during the comparative analysis of the three cell lines. The importance of these proteins on prostate cancer progression remains to be elucidated with further characterizations. The combination of the two dimensional liquid:liquid separation and mass spectral identifications was used to successfully analyze differential protein expression between multiple cell lines.

Keywords

PF2D; Prostate Cancer Progression

1. Introduction

Prostate cancer (PRCA) is the most common non-skin cancer in men, affecting 1 in 6 men. According to the American Cancer Society, there were more than 217,730 new cases diagnosed, and approximately 32,050 deaths, in 2010 alone¹. Mortality rates have decreased due to earlier detection through the prevalence of screening with the prostate specific antigen (PSA) test. The protein PSA, initially characterized in 1971², is a serine protease (EC 3.4.21.77) that is neither specific nor solely prostatic in origin. PSA is also found in breast³, lung⁴, uterine⁵ and renal⁶ cancer. Though not specific as a predictor of PRCA, PSA

^{© 2012} Elsevier B.V. All rights reserved.

Alan Eric Friedman PhD, Assistant Professor of Environmental Medicine, Director, University of Rochester Proteomics Center, Aab Institute for Biomedical Sciences, University of Rochester, Medical Center Box 611, 601 Elmwood Avenue, Rochester, NY 14642, Telephone: (585) 273-4066, AUTHOR EMAIL ADDRESS Alan_Friedman@urmc.rochester.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

in patients diagnosed with PRCA is an excellent marker for the disease attaining a metastatic state independent of treatment. To facilitate the understanding of PRCA etiology and provide an earlier and more specific diagnostic tool for prostate cancer detection, improved model systems for PRCA biomarker research are required.

The development of cancer model systems is valuable to understand the progression of the disease. However, few systems distinctly present all states of the disease progression within one model. Most model systems are developed using a single state of cancer or disease, such as the LNCaP prostate cancer metastasis model. The few models that do represent cancer progression are limited by difficulties in tracking all of the perturbations caused by disease progression. These systems are excellent at modeling the effects of a single perturbation on a "closed" system. However, being able to follow the progression of a disease through one consistent model allows a systems approach, providing a closer emulation of true disease progression. Close proximity of any model system to true disease physiology is essential for the evaluation of therapeutic targets. Here, we report the proteomic characterization of one uniform model system of prostate cancer progression, the Prostatic Human Epithelial Cancer (PHEC) cell lines, to develop a refined system for studying human PRCA.

1.1. Human Prostate Cancer Model

The PHEC cell lines, first developed by Cunha⁷, represent a unique cell line for the evaluation of PRCA progression. Various model systems have been developed to characterize PRCA. However, only a minority of these demonstrate cancer progression to metastasis, including TRAMP, Pten-null, Noble rat, and the Lobund-Wistar rat. Examples of those that do not include metastasis are Myc-null, LPG-TAg or "LADY", Nkx3.1 null, TbR-II-knockout (KO), Prb-AR-transgenic, IGF transgenics, (urogenital sinus mesenchyme) UGM+mPrERb-/-, and carcinoma associated fibroblasts+hPrE TRs. The drawbacks of these models are that the carcinomas are usually of non-human (rodent) origin, and they lack an analogous phenotype, the development of prostatic intraepithelial neoplasia (PIN)⁸.

Our PHEC model is derived from the common ancestor line of other human models $(BPH-1)^9$. Unlike these other models, however, the PHEC model progresses through all three cancer states seen *in vivo*, as well as developing the pre-cancerous PIN. While the etiology of PRCA remains unknown, the steroid hormones testosterone and estradiol-17 β are known to be involved in carcinogenesis of the prostate, likely through reaction with the androgen receptor¹⁰. These cell lines stimulate progression through these constitutive physiological human hormones, and it is the only model system that undergoes human epithelial malignant transformation and metastasis, and thus represents all stages of human carcinogenesis.

These cell lines originate from tissue recombination of the non-tumorigenic human prostate epithelial cell line (BPH-1) with embryonic stroma-urogenital mesenchyme (UGM) isolated from rat seminal vesicles. Tissue recombinants grown in control animals developed into orderly and benign prostate-like tissue (PHEC_{NT}), whereas grafts grown in hormone-treated hosts developed into cancer at 2 months (PHEC_T). At 4 months, growth progressed to malignant cancer with metastases (PHEC_M) to lymph nodes, lung, and liver. These cells now have the ability to be grown *in vitro*, with three distinct cell lines created at sequential time points to represent the three states of cancer progression, and have been shown to be human in origin¹¹. They model many of the same cell types, progression markers, and epigenetic behavior as human cancer progression. Therefore, it serves as an exceptional model system for the analysis of the physiological changes of PRCA progression at the cellular level.

1.3. Liquid:Liquid Separation System

We have applied the use of a PF2D protein fractionation system (Beckman Coulter) to our analysis of the PHEC cell line. This system has an advantage over conventional two-dimensional electrophoresis (2DE) as it allows identification of a new fraction of the proteome, which overlaps with the 2DE proteome by approximately 20%¹². In this system, samples are fractionated based on their pI and hydrophobicity, in contrast to the 2DE separations based on pI and molecular weight. Separation by PF2D employs a liquid:liquid system, based on liquid chromatography. The PF2D involves alternate physical separation properties and does not use a gel, so the resulting subset of proteins can be isolated to identify many proteins not seen with other methods. The PF2D system also preserves post-translational modifications routinely stripped during other separation techniques. Overall, the PF2D combines the benefits of liquid-based and gel-based separations to generate an alternate sample for further characterizations.

2. Materials and Methods

2.1.Culture and Lysate Collection of PHEC lines

Lysates analyzed in these studies were generated from the PHEC *in vitro* cell lines as described previously¹³. Briefly, PHEC_{NT}, PHEC_T, and PHEC_M cells were grown in RPMI 1640 medium containing 25 mM HEPES and L-glutamine (Invitrogen) supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1X primocin (Invivogen). Cells were grown at 37°C and 5% CO₂. When cells reached approximately 75% confluency in a T-150 flask, they were harvested using 0.25% trypsin containing EDTA (Invitrogen). Trypsin was inactivated by adding 10% FBS, and the cells were pelleted via centrifugation at 1500×*g* for 5 minutes at 4°C. The pellet was rinsed with HBSS (Invitrogen) and stored at -80° C until analysis. Frozen cell pellets, prepared from approximately 1×10⁸ cells, were lysed in a buffer of 6 M urea (Sigma), 2 M thiourea (Sigma), 10% glycerol (EM Science), 50 mM Tris-HCl pH 7.8–8.2 (JT Baker), 2% n-octylglucoside (Calbiochem), and 1 mM protease inhibitor (Sigma). The resulting samples were then vortex agitated for 30–60 seconds, incubated for 30 minutes at room temperature, and centrifuged at 20,000×*g* for 1 hour at 4°C to pellet the particulate matter. The cell lysate supernatant was exchanged into 3.5 mL Start Buffer (Beckman Coulter) using a PD10 buffer exchange column (GE Healthcare).

2.2. PF2D Liquid/Liquid Proteome Fractionation

Total protein concentrations of the lysates were measured at 280 nm using a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE, USA), and 5 mg of total protein solubilized in PF2D loading buffer was injected into the PF2D system. The first dimension separated by chromatofocusing (CF) using a proprietary eluent buffer (Beckman Coulter) flowing isocratically at 0.2 mL/min on a Beckman Coulter CF column. Fraction collection occurred in intervals of 0.3 pH units within a range of pH 8.5–4.0, and then every 8.5 min outside this pH range, with fractions collected in a 96-well deep-well plate in a chilled fraction collector. These samples were then re-injected automatically for the second dimension analysis, taking 250 µL per well. The separation of the second dimension incorporated standard reversedphase chromatography, performed on a non-porous $C_{18}\ reverse$ phase column (Beckman Coulter) with gradient flow of 0.75 mL/min from 0%B to 100%B over 30 minutes using 0.1% TFA in water for mobile phase A and 0.08% TFA in acetonitrile for mobile phase B. Second dimension fractions were collected into 96-well plates continuously from 6-24 minutes run time in 30 second intervals, and fractions were stored in the plates at -80° C until subsequent analysis by mass spectrometry. The second dimension elution parameters represent the standard in the field, and are routinely used to perform post-translational modification analysis for phosphorylations, methylations, dimethylations, and acetylations.

Results were visualized in Mapping Tools software (Beckman Coulter), where differential analysis was performed in the "DeltaVue" mode. Mapping Tools is limited in its ability to overlay samples, only allowing two samples to be overlaid at a time, creating a need for a new technique to view the three states of our model system simultaneously. To visualize plots of the three PRCA states of our model, the data files were read into Excel. We generated a spreadsheet to transfer the values from the Mapping Tools files, converting raw data values into absorbance and time values, which were then plotted and labeled by fraction number and pI.

2.3. Bottom-up Proteomics

Samples were selected for subsequent analysis based on the criteria of a two-fold change in intensity or a substantial change in peak shape. Although peaks were assumed to contain multiple species, a 2X increase in UV signal would reflect an increase in one or more of the peak components. This criteria was qualitative, serving only as a selection parameter for further analysis. Addresses for samples were determined using a spreadsheet generated internally based on timing and patterning of fraction collection in the second dimension. For each well selected for analysis, the corresponding wells in the other two cell lines were also analyzed to provide a true comparison of the full proteomic progression model. However, if a selected well address in one of the other cell lines did not contain a UV signal exceeding 0.01 AU in the primary chromatogram, the analysis of this sample was not performed. Repeated analysis determined individual peaks with signal intensities < 0.01 AU to be below the lower limit of detection for reliable mass spectrometric identification.

For samples selected, the wells were rinsed with acetonitrile, and the samples evaporated with a speedvac until 20 μ L sample remained. Samples evaporated below 20 μ L were adjusted to 20 μ L with 100 mM ammonium bicarbonate solution. Samples were reduced with 3 μ L of 10 mM DTT (Calbiochem) and alkylated with 2 μ L of 55 mM IAA (Sigma) before digestion with 375 ng trypsin (Promega). Digestion was stopped by the addition of 3 μ L of 1% TFA to a final concentration of 0.1% TFA, and digested samples were evaporated to dryness before reconstitution in 10 μ L of 5% acetonitrile with 0.1% formic acid in water. Samples were loaded into autosampler vials and placed in a cooled autosampler for LC-MS/MS analysis. LC separations were achieved on a 75 μ m × 15 cm C₁₈ PepMap column (3 μ m, 100 Å pore size) from LC Packings. Peptides were eluted with a gradient of 5–50% B over 35 minutes followed by 50–90% B for 10 minutes at a flow of 400 nL/min. MS/MS analysis was performed in-line with the LC on a Micro-TOF QII (Bruker Daltonics).

For MS/MS analysis, a survey scan was performed, followed by fragmentation (MS/MS) of the top three most abundant peaks in the survey spectrum. A spectral rate of 1.3 Hz was used for MS spectra and 0.7 Hz for MS/MS spectra. Argon was used as a collision gas, and the RF of the collision cell was used in sweep mode to ensure detection of low m/z ions. Peptides were identified via the MASCOT database (Matrix Science) by searching individual peptide mass data against the NCBInr database for human proteins with carbamidomethyl cysteine as a fixed modification and oxidized methionine as a variable modification¹⁴. MuDPit scoring was used, so peptides with scores \geq 38 were considered to have high homology, or a positive identification (p<0.05). Peptide identifications were accepted if the false discovery rate was less than 5% and a minimum of one peptide met the identity threshold.

2.4. Western Blot Analysis

Cells were grown and harvested as described above, and pelleted cells were lysed in 1X RIPA buffer. Protein concentration was determined using Amersham's 2D quant kit, and 50

 μ g protein for each sample was used for Western Blot analysis. Here, proteins were separated on a 1D SDS-PAGE gel (4–20% TRIS-Glycine from BioRad) then transferred to PVDF membrane using an iBlot System (Invitrogen). Membranes were blocked with 10% milk in TBST. Primary antibodies were either α -tubulin for loading control or maspin (Cell Signaling). Detection occurred through HRP-coupled secondary antibodies.

3. Results and Discussion

We undertook the study of the PHEC cell lines using the PF2D system to define the differences between the three states of our cancer progression model. Our investigations have accomplished the bottom-up proteomic analysis of the three PHEC states and have identified several species of interest corresponding to specific cancer states. In doing so, these studies also allowed an evaluation of the PF2D liquid separation format.

3.1. PF2D-Differential Liquid:Liquid Separation of PHEC Cell Line

Output from PF2D separations occurs initially as a series of single chromatograms of the different separations from the two-dimensional HPLC system, as shown in Figure 1. We extracted the 214 nm UV data signal for each chromatogram and compared each as in Figure 1C. These chromatograms are then converted to pixelated graphs, visualized using the software "Mapping Tools" (Beckman Coulter) to produce an image similar to that generated when analyzing two-dimensional gels. This "pseudo" 2D gel image was then compared between multiple proteomes for differences, with color intensity in the image corresponding to concentration of protein eluted from the columns. For each proteome analyzed, 5 mg protein was injected, allowing for direct comparison between proteomes based on changes in protein expression in the 2D images. Figure 2 illustrates the digital UV output from the PF2D system of the proteomes for PHEC_{NT}, PHEC_T, and PHEC_M cell lysates. Between each pair of individual state images is a comparison spectrum. Circles have been added to highlight the differences between the proteomes of the two cell lines being compared. These comparison spectra are referred to as the "difference spectrum" between the proteomes of PHEC_{NT} vs. PHEC_T, and PHEC_T vs. PHEC_M. Though UV spectral comparisons are done to select fractions for MS/MS identification, it is understood that each UV peak likely contains multiple proteins. Mass spectral analysis is used for all comparative conclusions regarding single proteins and characterizations of expression throughout the cancer progression model.

3.2. Identification of Altered Protein Production Between Progression States

Based on comparative analysis of the proteomes of the three PHEC cell lines, the liquid fractions were identified for further characterization using for bottom-up proteomics. Retention time was used to determine the well address for each fraction of interest, and comparisons were made only between the exact two-dimensional positions between proteomes. The selected samples underwent tryptic digestion and mass spectrometry for protein identification. In Figure 2, the circled differences were identified in this manner, and a condensed summary of proteins identified is given as Table 1. Full quantitative assessment of total expression levels of proteins was not performed. The identification and expression of proteins discussed refers to relative qualitative expression between cancer progression states.

An overview of Table 1 reveals that the some proteins have been identified in more than one sample, or at multiple elution points during the 2D chromatography separation process. This can be understood by classifying the identifications and localizations into three general groups: 1) proteins that are localized to the same first dimension fraction but have different retention times in the second dimension, categorized as hydrophobic effects, 2) proteins in adjacent first dimension fractions having similar retention times in the second dimension,

Lapek et al.

different fractions in both first and second dimensions, categorized as modification effects. As these separations use liquid chromatography to resolve complex protein mixtures, the resulting protein fractions have a range of elution points, similar to a normal distribution curve. The fractionation ranges possible due to hydrophobic and focusing effects are compounded by the two separate dimensions of the PF2D separation, creating mixtures of proteins with multiple final endpoints.

Proteins eluted from the PF2D were fractionated by defined intervals, using pH units for the first dimension and time for the second dimension. If a protein began to elute at a pH or time near the end of one fraction qualifier, it could finish in a second fraction qualifier, thereby splitting the protein into multiple fractions. This can be confounded further if the protein elutes into two fractions in the first dimension and two in the second dimension, essentially allowing it to be identified in four separate fractions. Depending on the biochemical and conformational properties of the protein, elution can occur across a very narrow fraction range or a wider one. In this study, one example of impact of these effects was the protein eukaryotic translation elongation factor (eEF1A1). EEF1A1 was found in fractions 13, 17 and 18 (Figure 3), indicating elution over a 1.5 minute period, from retention times 16.5–18 minutes. Since the second dimension collects a fraction every 30 seconds, eEF1A1 was identified in 3 separate fractions. This is also an example of a protein with focusing effects, as it is found in first dimension fractions 12 and 13 (pI 7.4–7.7 and 7.1–7.4, respectively).

Proteins with multiple elution points can also originate from modification effects, the third classification. This general term refers to proteins with structural or conformational changes that impact the chemistry of separation. Included in this category are proteins with various post-translational modifications (PTMs) different isoforms of one protein, analogous proteins, and proteins with point mutations. PTMs and point mutations can lead to subtle or drastic changes in pI, depending on the amount and nature of the alteration¹⁵. Proteins that have non-covalently bound species, such as histones, experience an overall change in pI due to molecular complexation. Protein degradation products are also commonly identified in proteomic analyses. While samples were lysed with buffer containing protease inhibitors to prevent proteolysis during sample preparation, protein degradation occurs regularly within cells, so degradation products were expected. Degradation can lead to changes in tertiary or quaternary structures, so a single degraded protein could have several conformational structures present within a sample. Each conformation interacts with the chromatographic column matrix and mobile phases with slight variations. Depending on the level of degradation present, a single protein could be identified, but with multiple elution points due to changes in chemical interactions with the columns used in the PF2D separation. Similarly, each fraction contains multiple proteins in the same eluent, so all comparative analyses are based upon MS/MS identification of single proteins within complex mixtures.

Further analysis of the results in Table 1 indicates that, in most cases, more than one protein was identified in each fraction. This can be attributed to the biochemical properties of the protein separation and fraction collection methods. Because the separation involves twodimensional chromatography, as opposed to a traditional single dimensional separation, the elution parameters cannot be optimized simultaneously for both separation chemistries. However, as the chromatography was designed to separate proteins for the subsequent identification by mass spectroscopy, the separation parameters do not need to resolve individual species per peak or fraction collected. Multiplicity of proteins within peaks is balanced by the power of the detection system, so the separation method serves only to enhance the resolution and sensitivity of the subsequent identification. There are multiple advantages to this technique over more routine methods, such as single dimension chromatography or gel electrophoresis. The basis of the separation is liquid chromatography, so samples are injected in solution and collected as fractions of eluent. This allows the proteins to remain in solution throughout the full separation process, eliminating dry-down and reconstitution steps that can lead to sample loss. The liquid-based separation procedure allows for preservation of PTMs for subsequent identification. Collecting fractions in solution leads to characterization of modifications directly by mass spectrometry, providing a more accurate picture of the nature of the proteins within the cells of origin. This creates a more reliable picture of the proteins within the cells than can be generate from gel-based separation techniques routinely used in proteomic evaluations.

In addition to the advantages for characterizing whole proteins, the use of two-dimensional chromatography for proteomic separations introduces a different set of proteins into the proteomes being studied. While gel-based separations exclude high mass, aggregated, and hydrophobic proteins, such as those found in cell membranes and within subcellular architecture, solution-based separations allow the analysis of all cell lysate proteins injected into the chromatograph. As such, a different subset of the proteome becomes available for identification and characterization.

The comparative analysis of the three proteomes of the PHEC cell lines showed identifications of proteins from a variety of cellular locations. As shown in Figure 4, proteins typically associated with the nucleus increased as the cells progressed toward metastasis. The overall complexity of distribution of protein localizations within the cell changed dramatically as cancer progressed. Cells in the non-tumorigenic state localized to 9 sites, while tumorigenic cellular proteins occurred in 12 locations. Interestingly, the metastatic cellular proteins identified were localized to only 5 cellular places. The combination of the inclusion of higher mass and hydrophobic proteins with the ability to evaluate PTMs and binding partners introduces a powerful tool to the understanding of biomolecular interactions within the cell membrane and within the architecture of the cell. This information would not be available with gel-based methodologies.

With these techniques, we generated a proteomic comparison of the three cancer progression states of the PHEC model. The highest frequencies of proteins identified in the fractions of interest between the three cell lines were members of the cytokeratin family (KRT), filamentous protein polymers responsible for the structural integrity of epithelial cells. Others have shown evidence for the correlation between changes in cytokeratins and cancer progresses to a malignant state. In PRCA, cytokeratins have shown differential expression from human prostate tissue depending on the progression state. A tumor-associated species, specifically present in tumors and absent from normal and most benign prostatic hyperplasia samples, was identified to be a proteolytic fragment of KRT8 that showed a mass reduction and a change in pI value¹⁶. Extensive fragmentation of KRT molecules by these proteases has been suggested to support the participation of cytokeratins in malignancy¹⁷.

In the PHEC model, cancer progression across the three states showed decreased total expression of keratins, with 42 identifications in 21 fractions of the non-tumorigenic cells, 41 identifications in the same fractions of tumorigenic cells, and 17 identifications in those of metastatic cells. Of the identifications made in the chosen fractions, the non-tumorigenic cells displayed 30 different types of keratins, while only 15 and 9 types of keratins were displayed in the tumorigenic and metastatic cells, respectively, as shown in Figure 5. Their identifies are given in Table 1. This level of change in keratin production and variety as cells morph from a healthy state into metastatic cancer cells poses an interesting point of speculation regarding the role of keratins in cancer progression. Keratins perform a predominantly structural role, aligning into large aggregate assemblies within cells. Our data

showed the progression to malignancy in the PHEC cell lines leads to altered and inconsistent morphology within tumorigenic and metastatic cell cultures. The observed morphological changes could be the result of a limited expression of keratins, or to the introduction of keratin expression types not typically found in the normally replicating cells. These findings support extensive reports in the literature of the phenotypic changes cells undergo as they transform into fully malignant cancer forms.

The second most prevalent protein family found in the comparison of the three progression cell lines was the histone family. These proteins showed a trend opposite to that of the keratin family, with histone expression and variety increasing across the progression states toward metastasis, illustrated in Figure 5. Seven individual histones representing 6 histone types were identified in the non-tumorigenic cells, as opposed to 20 identifications representing 9 types in the tumorigenic state and 23 identifications representing 10 types in the metastatic state. Histones are predominantly responsible for packaging chromosomes. Most importantly, histones play a crucial role in epigenetic variations, and they are drastically altered in cancer formation. One of the key mechanisms of tumor formation is the silencing of genes associated with cancer by epigenetic regulators¹⁸, and epigenetic variations have been suggested to be indicative of disease prognosis, including prostate cancer¹⁹. Histones are able to alter the degradation processes and signaling mechanisms of the healthy cell through their own modifications, fundamental cellular changes that could lead to cancer progression.

Of those proteins identified from the comparison of the three cancer states, individual proteins of interest have shown to be differentially expressed between the progression states and have previous associations with cancer in the literature. Found in fraction 3, maspin (SERPINB5) is a member of the serpin super family of proteins, known for their antiprotease activity. This protein was discovered through its tumor suppressive properties. Maspin is a non-inhibitory serpin showing importance in preventing metastasis in breast²⁰ and prostate²¹ cancers. In the PHEC system, the maspin protein elutes at only one pI (6.1–6.4), indicating only one form present. Maspin shows a clear reduction in concentration as the cells develop into cancer and metastasize (Figure 6). The initial reduction in UV peak area seen in the PF2D was confirmed using immunoblot analysis, as shown in Figure 6. This behavior reflects that observed in the literature and substantiates the potential of maspin as an indicator of the transformation from tumorigenic to metastatic cancer.

Another protein differentially expressed between the three cancer states is HSP70. The HSP70 proteins are a family of proteins, including the two major cytoplasmic isoforms heat shock protein 70 (HSP70) and heat shock 70 kDa protein 8 (HSC70), that assist in a broad set of functions as part of the cellular machinery for protein folding and protection of cells from stress. As one of the chaperone proteins, HSP70 may have a role in cancer because it has been found in increased abundance in cancer cells, though not as a reliable marker to predict the reoccurrence of cancer²². The poor diagnostic ability of HSP70 in cancer evaluations may be caused by the failure to monitor the precise species. In the PHEC system, both HSP70 and HSC70 were identified. In the PHEC_{NT} cells, HSP70 and HSC70 were identified separately in multiple fractions. In the PHEC_T cells, HSP70 and HSC70 were identified together in the same two fractions. However, in the PHEC_M cells, only one fraction contained both HSP70 and HSC70. The presence of HSC70 in the metastatic cells corroborates previous findings that HSC70 is over-expressed in the metastatic state²³. Overall, the presence of multiple fractions indicates differing forms of the HSP proteins, suggesting there might be post-translational modifications on these proteins that could change their cellular functions throughout the progression of prostate cancer.

Elongation factor 1 alpha (eEF1A) is also found in several places in the comparative proteomes of the three PHEC cell lines. Physiologically, eEF1A has shown expression in human prostate tumors, while absent in normal human prostate tissue²⁴, and recently has been shown to interact with phospho-Akt to regulate proliferation, survival and motility of breast cancer cells²⁵. In addition, overexpression of eEF1A has been demonstrated in cell lines modeling pancreatic cancer, leukemia and osteosarcoma²⁶. In our PHEC model of prostate cancer progression, eEF1A occurs in all three progression states at multiple pI and hydrophobicity levels, as shown in Figure 3. Many PTMs have been shown on eEF1A²⁷, which could explain the various forms eluted in the separations.

The identification of these selected proteins of interest from the comparative analysis of the cancer progression showed one striking feature among all them: the presence of multiple elution points from the two-dimensional chromatography separations employed. As previously described, this could indicate the presence of post-translational modifications, leading to considerations of the purpose of these PTMs. Proteins generally undergo PTMs for regulation of cellular processes. The PHEC model undergoes the full progression of PRCA from non-tumorigenic cells to metastatic cells, so changes in the modifications of proteins across this progression could be suggestive of the regulatory role of the proteins evaluated in the development of cellular metastasis.

The key to understanding the mechanism of cancer metastasis lies in the ability to capture a snapshot of the cell at rapid time intervals as the cells actively convert to the metastatic state, introducing a possible kinetic model of cancer metastasis not previously reported. This allows the disassembly and evaluation of individual aspects of the cell at each time point to consider individually the changes occurring simultaneously physiologically, rather than following only a single molecule or group of species of interest. Gathering such a "cellular snapshot" provides a more complete analysis, allowing a characterization of the molecules and organelles performing together to lead the cell to a metastatic endpoint. While this scenario sounds ideal, it is not trivial experimentally. Such an undertaking requires the ability to capture cells directly at successive time points, from which the lysates undergo total cellular analysis for protein changes. In addition, the cells studied must be capable of transforming fully from healthy prostate cells to metastatic cancer cells.

The purpose of this work is to introduce the model and methodologies by which a "cellular snapshot" study of human prostate cancer metastasis will begin. The PHEC model provides the necessary cellular component – humanized *in vitro* cell lines with identical genetic backgrounds that provide the full cancer progression to metastasis. The origin of all three PHEC cell lines from the same genetic source provides uniformity to the analysis, eliminating the variable background proteins unavoidable when multiple cell lines are used to cover the full cancer progression. This allows much more sensitive detection of subtle changes in proteins, such as PTMs and isoforms, that could be key facets to understanding metastatic mechanisms.

The combination of the PHEC human prostate cancer model system with an alternate proteomic analysis using two-dimensional HPLC/MS/MS introduces a new aspect to cancer research. This concept could provide a fundamentally unique perspective on the manner in which cellular mechanics are studied. More importantly, these tools together provide a model for human prostate cancer research that has not been studied previously, visualizing differences in individual proteins from the milieu of cellular components changing as cells metastasize.



Proteomic characterization of a novel *in vitro* prostate cancer model system

J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2013 April 15.

>



Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Michelle Friedman for insightful discussion and editing and the University of Rochester Proteomics Center for instrument time. PF2D instrumentation was funded by FA9550-04-1-0430 (DOD) AEF derived funding from (NIH), 1 UL1 RR024160-1, National Institute of Environmental Health Sciences Training Grant ES07026, and Center Grant ES01247 and U of R start-up funds (AEF).

References

- 1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277–300. [PubMed: 20610543]
- Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of " seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi. 1971; 25(4):322– 324. [PubMed: 5106556]
- Poh BH, Jayaram G, Sthaneshwar P, Yip CH. Prostate-specific antigen in breast disease. Malays J Pathol. 2008; 30(1):43–51. [PubMed: 19108411]
- Zarghami N, D'Costa M, Tsuyuki D, Asa SL, Diamandis EP. Expression of the prostate specific antigen gene by lung tissue. Clin Cancer Res. 1997; 3(7):1201–1206. [PubMed: 9815800]
- Clements J, Mukhtar A, Ehrlich A, Yap B. Glandular kallikrein gene expression in the human uterus. Braz J Med Biol Res. 1994; 27(8):1855–1863. [PubMed: 7749374]
- Rae F, Bulmer B, Nicol D, Clements J. The human tissue kallikreins (KLKs 1–3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology. 1999; 45(1–3):83–88. [PubMed: 10614994]
- Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, Cunha GR. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer. 2006; 118(9):2123–2131. [PubMed: 16331600]
- Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59(19):5002–5011. [PubMed: 10519415]
- 9. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003; 107(1):1–10. [PubMed: 12925950]
- Cunha GR, Lung B. The importance of stroma in morphogenesis and functional activity of urogenital epithelium. In Vitro. 1979; 15(1):50–71. [PubMed: 437808]
- 11. (a) Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol. 1994; 8(2):230–239. [PubMed: 8170479] (b) Wang X, Colby JK, Yang P, Fischer SM, Newman RA, Klein RD. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis. 2008; 29(1):120–128. [PubMed: 17942462] (c) Voelkel-Johnson C, Voeks DJ, Greenberg NM, Barrios R, Maggouta F, Kurtz DT, Schwartz DA, Keller GM, Papenbrock T, Clawson GA, Norris JS. Genomic instability-based transgenic models of prostate cancer. Carcinogenesis. 2000; 21(8):1623–1627. [PubMed: 10910968]

- Billecke C, Malik I, Movsisyan A, Sulghani S, Sharif A, Mikkelsen T, Farrell NP, Bogler O. Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles. Mol Cell Proteomics. 2006; 5(1):35–42. [PubMed: 15951525]
- Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol. 2004; 92(4):221–236. [PubMed: 15663986]
- Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999; 20(18):3551– 3567. [PubMed: 10612281]
- 15. (a) D'Antonio M, Borrelli F, Datola A, Bucci R, Mascia M, Polletta P, Piscitelli D, Papoian R. Biological characterization of recombinant human follicle stimulating hormone isoforms. Hum Reprod. 1999; 14(5):1160–1167. [PubMed: 10325254] (b) Smith-Beckerman DM, Fung KW, Williams KE, Auersperg N, Godwin AK, Burlingame AL. Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer. Mol Cell Proteomics. 2005; 4(2):156–168. [PubMed: 15591324] (c) Saldanha RG, Xu N, Molloy MP, Veal DA, Baker MS. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer. J Proteome Res. 2008; 7(11):4792– 4806. [PubMed: 18808175] (d) Davis AJ, Carr JM, Bagley CJ, Powell J, Warrilow D, Harrich D, Burrell CJ, Li P. Human immunodeficiency virus type-1 reverse transcriptase exists as posttranslationally modified forms in virions and cells. Retrovirology. 2008; 5:115. [PubMed: 19091128] (e) Itkonen O, Helin J, Saarinen J, Kalkkinen N, Ivanov KI, Stenman UH, Valmu L. Mass spectrometric detection of tyrosine sulfation in human pancreatic trypsinogens, but not in tumor-associated trypsinogen. FEBS J. 2008; 275(2):289–301. [PubMed: 18076654]
- 16. Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, Nicolo G, Boccardo F, Galli S, Patrone E, Balbi C. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem. 2000; 79(3): 471–485. [PubMed: 10972984]
- (a) Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer. 2001; 34 Suppl 2:S65–S69. [PubMed: 11720744] (b) Linder S. Cytokeratin markers come of age. Tumour Biol. 2007; 28(4):189–195. [PubMed: 17717426]
- Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009; 50(4):455–463. [PubMed: 19718392]
- Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br J Cancer. 2009; 100(2):240–245. [PubMed: 19002169]
- Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 10(1):32. [PubMed: 20132554]
- 21. Hall DC, Johnson-Pais TL, Grubbs B, Bernal R, Leach RJ, Padalecki SS. Maspin reduces prostate cancer metastasis to bone. Urol Oncol. 2008; 26(6):652–658. [PubMed: 18367129]
- 22. (a) Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, Valdman A, Egevad L. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS. 2008; 116(10):888–895. [PubMed: 19132982] (b) Maehara Y, Oki E, Abe T, Tokunaga E, Shibahara K, Kakeji Y, Sugimachi K. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer. Oncology. 2000; 58(2):144–151. [PubMed: 10705241]
- 23. Deichmann M, Polychronidis M, Benner A, Kleist C, Thome M, Kahle B, Helmke BM. Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases. Int J Oncol. 2004; 25(2):259–268. [PubMed: 15254721]
- Shen R, Su ZZ, Olsson CA, Fisher PB. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci U S A. 1995; 92(15):6778–6782. [PubMed: 7542776]
- 25. Pecorari L, Marin O, Silvestri C, Candini O, Rossi E, Guerzoni C, Cattelani S, Mariani SA, Corradini F, Ferrari-Amorotti G, Cortesi L, Bussolari R, Raschella G, Federico MR, Calabretta B. Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Molecular cancer. 2009; 8:58. [PubMed: 19646290]

J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2013 April 15.

- 26. Selga E, Oleaga C, Ramirez S, de Almagro MC, Noe V, Ciudad CJ. Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome medicine. 2009; 1(9):83. [PubMed: 19732436]
- (a) Zobel-Thropp P, Yang MC, Machado L, Clarke S. A novel post-translational modification of yeast elongation factor 1A. Methylesterification at the C terminus. J Biol Chem. 2000; 275(47): 37150–37158. [PubMed: 10973948] (b) Rosenberry TL, Krall JA, Dever TE, Haas R, Louvard D, Merrick WC. Biosynthetic incorporation of [3H]ethanolamine into protein synthesis elongation factor 1 alpha reveals a new post-translational protein modification. J Biol Chem. 1989; 264(13): 7096–7099. [PubMed: 2708357] (c) Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P, Caraglia M. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ. 2007; 14(5):952–962. [PubMed: 17332776] (d) Dapas B, Tell G, Scaloni A, Pines A, Ferrara L, Quadrifoglio F, Scaggiante B. Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers. Eur J Biochem. 2003; 270(15):3251–3262. [PubMed: 12869201]

Lapek et al.



Figure 1.

Chromatographic separation of the three cell lines of the PHEC model. Equivalent amounts of protein from the lysis of the three individual cell lines were separated by pI in the first dimension and hydrophobicity (reversed-phase) in the second dimension. Fractions were collected in the first dimension in the range of pI 4.0–8.3 and in the second dimension for retention times 6–24 minutes, with UV detection at 214 nm for both dimensions. A) A UV chromatogram is acquired for each fraction within a given sample. B) Mapping Tools is used to yield a composite image showing a "pseudo" 2D gel for each sample. Each lane represents one fraction. Fractions can then be compared between samples (boxed section). C) Relative quantitation can be determined by overlaying the fraction chromatograms from the three samples.

Lapek et al.



Figure 2.

Proteomic difference maps for the comparison of the $PHEC_{NT}$, $PHEC_{T}$ and $PHEC_{M}$ cell lines show the PF2D profiles for the respective cell lines from the pI range of 4.0 to 8.3. Between each single cell line profile is the composite difference map comparing two cell lines: red and black for $PHEC_{NT}$ vs. $PHEC_{T}$, and black and blue for $PHEC_{T}$ vs. $PHEC_{M}$. In the profiles, the intensity of the band color gives a relative intensity for that sample, with a darker band correlating to a higher protein concentration as compared to another spot of lower color intensity. The difference maps also show relative intensity, with the color indicating the sample of origin. Circles indicate samples that were recovered for mass spectrometry analysis and identification, with numbers corresponding to information in Table 1. Lapek et al.



Figure 3.

Sites of PF2D where eukaryotic translation elongation factor (eEF1A1) Proteomic difference maps for the comparison of the PHEC_{NT}, PHEC_T and PHEC_M cell lines show the PF2D profiles for the respective cell lines from the pI range of 4.0 to 8.3. Between each single cell line profile is the composite difference map comparing two cell lines: red and black for PHEC_{NT} vs. PHEC_T, and black and blue for PHEC_T vs. PHEC_M. In the profiles, the intensity of the band color gives a relative intensity for that sample, so a darker band correlates to a higher protein concentration in that spot as compared to another spot of lower color intensity. The difference maps also show relative intensity, with higher color intensity from one sample versus the other indicating a higher in abundance in this sample than the one to which it is compared. Circles indicate samples that EEF1A1 was recovered.



Figure 4.

Subcellular localization breakdown of identified proteins. Proteins in categories with one or more (+) in them are uniquely counted in that category and not the individual categories comprise up that category. A) Subcellular localization of total proteins identified from all three states combined. B) Localization of proteins identified from PHEC_{NT} lysates. C) Localization of proteins identified from PHEC_T lysates. D) Localization of proteins identified from PHEC_M lysates.

Lapek et al.





Figure 5.

A comparative analysis of the distribution of histones and keratins within the three PHEC model cell lines. The colors within each bar represent the number of identifications made in the fractions characterized for each cell line. The size of each colored segment represents the number of identifications of a species made within each of the separate cell lines.

Lapek et al.



Figure 6.

Identification and verification of a difference in abundance of the serine protease inhibitor MASPIN. A) Overlaid chromatograms of the fraction containing MASPIN in the three samples. The arrow indicates the peak associated with the identity. B) Sequence coverage for the LC-MS/MS identification of MASPIN with the corresponding MASCOT score. C) Western blot analysis to verify the difference in abundance observed by LC-MS/MS. Alpha-tubulin was used as a loading control.

Table 1

A summary of proteins identified by mass spectrometry after separation by 2D HPLC. Information pertaining to location in first and second dimension plates of the PF2D run, MASCOT score, accession number and number of identified peptides is also given for each protein. Mascot scores >38 indicate homology or identity in the database searching lead to an identification of a protein of interest. Spot number refers to the location number circled in Figure 2.

16 12 14 11 15 44 1 11 13 11 15 14 15 14 15 14 15 17 14 15 15 17 17 18 17 18 17 18 17 18 18 17 18 18 17 18 </th <th>Ist Dimension Fraction #</th> <th>Spot Number</th> <th>Protein ID</th> <th>Cell Line</th> <th>accession</th> <th>Top MASCOT score</th> <th>Peptides</th>	Ist Dimension Fraction #	Spot Number	Protein ID	Cell Line	accession	Top MASCOT score	Peptides
21.2.2.17, 19.10.20 19.15.4.9 Nummin NT 8/12320321 79.120.60 0.4 13.13 12.13 Nummin NT 8/153305 1.4 2 13.13 12.13 Nummin NT 8/153305 1.4 2 13 1.4 A <td>16</td> <td>12</td> <td>aflatoxin aldehyde reductase AFAR</td> <td>т</td> <td>gi 2736256</td> <td>45</td> <td>2</td>	16	12	aflatoxin aldehyde reductase AFAR	т	gi 2736256	45	2
bi, 10 11, 13 annow a 1 NT ell 1573280 64 2 13 9 5, 17 APPlieding caster, sub-family motion T ell 43308 3.1 1 19 4 CS control ar papoling subscriptibility protiin T ell 43308 3.1 1 17 4 CS control ar papoling subscriptibility protiin T ell 23855 4.0 1 13 13 CSP - Econtronce potein E T ell 23855 4.8 1 15 12 12 13 13 13 13 13 13 13 14	21, 23, 17, 19, 10, 23	11, 1, 5, 4, 9	Albumin	NT, T, M	gi 122920512	75 , 126, 45	5, 4, 1
19.1917APABinding cassets, usb-family member 2Te 1195740(4)2195CS cellut rapingsoin succe philong one in a construction succe philong one	16, 13	12, 13	annexin a1	NT	gi 157829895	64	2
19 5 appeing protein alpha attom: tryssingen T ell (13308) (15138) 51.1 1 17 4 Cost cluits appoing susceptibility protein attom: tryssingen T ell (13006) 51.1 1 1 3 Cost cluits appoing susceptibility protein attom: tryssingen T ell (13006) 61.2 1.1 3 Cost cluits appoing susceptibility protein attom: tryssingen T ell (13006) 61.2 1.1 61.2 1.2	13, 19	5, 17	ATP-Binding cassette, sub-family F member 2	т	gi 119574400	43	2
173.8CS cellul approximation subscriptiling motionTell plassis4.2112.13.8CNP4 controlence proteinTell plassis4.2113.11.0CNP4 controlence proteinTell plassis4.2121.151.31.3Plassis0.11.31.31.5	19	5	capping protein alpha	т	gi 433308	51	1
11 3 cattoric regime potenti T eji 123555 54 2 13 13.2 13.30 elionde intracellular channel 1 NT eji 19855 40.7 1.2 11.16.0.11,11 12.2 12 enume that as all channel intrace lular channel 1 NT eji 19855 40.7 1.5 21.19 55.89 enume that as all channel intrace lular channel intrace share factor 1515 hordef T eji 18956 40.7 4 16.13.12, 12.00.03 15.9 Heat shock particle and exchange factor 1515 hordef 10.15737 40.577 1.2 12.0 0.3 Parabelogical advector exchange factor 1515 hordef 10.15737 45.57 1.2 12.0 13.14,15,12 1.5,13,1 11.54,12 1.2,13,13 1.2,23,13,13,13,13 1.2,23,13,13,13,13,13,13,13,13,13,13,13,13,13	17	4	CAS cellular apoptosis susceptibility protein	т	gi 951338	42	1
1731CNP-E controlmer potein ENTg 286540113.2013.20Cratine kname 3NT.Ng 285545.0115.1012.10.11.212.10.11.410.10NT.Ng 285045.0115.1012.10.11.410.10NT.Ng 285045.011179Savapotic initiation factor 3.0Tg 285046.01116.13.22.12.012.6.13.7Mest hock protein 70Tg 155046.51115.13.22.12.012.6.13.7Mest hock protein 70Tg 155046.51113.19.11.10.105.1.7.8Interiogeneous nuclear inbundeoprotein 41NT.g 150040.201113.19.11.11.105.1.7.8Interiogeneous nuclear inbundeoprotein 41NT.g 150010.101113.19.11.11.105.1.7.8Interiode RiseNT.g 150010.1011113.19.11.11.1015.1.1815.1.1815.1.1811	21, 17	3, 8	cationic trypsinogen	т	gi 11120626	54	2
13.2113.20biomedia metagellular channel17.10002.2217creatine inance of the origination factor i alphaNT.1011805540.21.6.721.15.012.5.012.5.012.5.012.5.012.5.012.5.012.5.01.5.721.1512.12.2.012.5.1.3.7Restandor factor i AlphaNT.0115534244.020.2202010Restandor factor i AlphaNT.0115534244.020.221.210Restandor factor i AlphaNT.0115537544.020.221.121.310.5.1.3Restandor factor i AlphaNT.011.212.4.221.2.1.2.1.05.3.1Restandor factor i AlphaNT.011.212.4.212.5.1.112.1.2.1.1.1.1.1.1.1.1.1Ntarone RESNT.011.212.4.212.5.1.112.1.2.2.2.1.1.1.1.1.1.1.1.1.1.1Ntarone RESNT.011.212.4.1.1.1.112.1.2.2.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	17	3	CENP-E centromere protein E	т	gi 29865	40	1
2117creating thanse-8NTNTg 12963148121, 1613, 84elemagtan factor laiphaNT.n 1243312, 173, 111744caling factor 113.8%Tn 1243312, 173, 1116, 12, 12, 10, 2012, 0, 13, 714, 1414711045444716, 12, 12, 10, 20, 10, 10, 1410, 1414, 14147110454447171414, 14, 1414, 1414141414141417, 1411, 14, 1214, 14, 1414, 14, 14141414141413, 14, 1214, 14, 1414, 14, 1414, 14, 1414, 14, 14	<mark>13,</mark> 21	13, 20	chloride intracellular channel 1	NT, T	gi 895845	41, 76	2, 2
21, 16, 10, 12, 12, 10, 10, 13, 12 12, 12, 10, 10, 13, 12 12, 12, 10, 10, 13, 12 12, 12, 10, 10, 13, 12 12, 12, 10, 10, 13, 12 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13	21	7	creatine kinase-B	NT	gi 180555	48	1
11. 19. 8 18. 8 18. 70 19. 70 19. 70 10. 7	21, 16, 10, 12, 16, 10, 13, 12	12, 1, 2, 14,	elongation factor 1 alpha	NT, T, M	gi 181965	69, 128, 211	1, 6, 7
11.10 58.9 EMPO NT. T 9 120333 12.1.1.1 17 4 Guanne nudeotide exchangt factor J15-MboGF T 9 1405793 40.3 4.2.2.2 16.13.2.12.2.0.2.30 10.3.0.3.1.2 10.3.0.0.3.1.1.1.2 10.3.0.0.0.1.1.1.2		18, 8					
21 9 extarped initiation factors M T 9 812775 46 4 2 16 12, 12, 12, 12, 10, 10, 13, 1 Heat shock protein 70 HT, 14, 137557 200 10 1 2, 19 30 hematological and neurological express ef 1 M 91/205377 6, 57 1, 3 12, 10, 13, 17, 12, 10, 15, 14, 13, 16 15, 17, 13 Hinde protein 20, 100 1, 17 91/205371 6, 57 1, 3 12, 12, 30, 13, 17, 19, 12, 13, 15, 6, 21, 13 Histone H4A T, 14 91/156531 442, 100 13, 14 12, 12, 33, 16, 13, 11, 13, 14, 12, 24, 13, 50 13, 14, 12 14, 14 110 HT 91/150531 442, 100 13, 11, 13 12, 12, 23, 16, 13, 11, 13, 14 16, 14, 15, 6, 21, 14 16, 12 Kerain 13 HT 91/15056 107 2 13, 12, 14, 12, 14, 12 16, 12, 12, 7 Kerain 13 HT 91/150303 137 9 14, 12, 14, 12 Kerain 12 HT 91/15010 137 9 14 14 14	21, 19	5, 8, 9	ERP60	NT, T	gi 729433	<mark>82,</mark> 117	3, 11
17 4 Guanne nucleotide exchange factor p115-RhoEff T. g 1543241 20 42 22 10 10 61.5 21.2 10 hetenotogical and neurological expressed 1 MI g 1705877 6.0 1 12.19 5.9 hetenotogeneous nuclear rhooudeepotein H1 MI g 1505831 45.5 1.5 13.19, 10.13, 14 5.4, 13.5, 12 histone H2 Mistone H2 g 1506831 42.5, 20 5.7 13.19, 10.13, 14 1.5, 17.8 Histone H2 Mistone H2 g 1506831 105, 26.2, 114 3.10, 7 12.19, 23, 16, 13, 21, 13, 10, 15, 16 Li, 11, 15, 5 Keratin 1 MI g 1507985 100, 22.112 3.10, 7 12.19, 23, 16, 12, 21, 13, 13, 13, 13, 13, 13, 13, 14 Keratin 13 MI g 1507985 101 2 13.2 13, 13, 14 Keratin 13 MI g 1507984 107 2 13.2 13, 7 Keratin 13 MI g 1507984 101 2 14.2, 12, 13, 7 Keratin 13 MI	21	9	eukaryotic initiation factor 5A	т	gi 4261795	46	4
16. 13. 21. 21. 20. 20. 12. (A. 13. 7, Heat Sched protein 70 NT, T. M. gil 386785 208, 366, 360 14. 24. 22 22 19 hematological and neurological expressed 1 M. gil (705377) 40 1 12. 12. (J. 13. 7), 21. 0, 13. 7), 21. 0, 14. 14, 17, 13. 9 14. 14. 14. 14. 14. 14. 14. 14. 14. 14.	17	4	Guanine nucleotide exchange factor p115-RhoGEF	т	gi 1654344	44	2
20 hematological and neurological expressed 1 M pl [700377] 400 1 22, 19 5,9 heterogeneous nuclear ribonucleoprotein H1 NT, T gl [503173] 46,57 1,5,13 13, 14, 12, 14 1,5,21,13 Histone H2A NT, T gl [503173] 427,486,716 7,15,13 11, 23, 01, 31, 71, 21, 2 Histone H2A T M gl [503173] 427,486,716 7,15,13 12, 13, 23, 13, 17, 12, 12 Histone H2A T M gl [150853] 142, 100 15, 14 12, 12, 23, 13, 12, 11, 15, 6, 12 Histone H4A NT gl [130786] 107 2 12, 12, 23, 13, 12, 13, 15, 8, ratin 12 NT gl [130786] 107 2 13, 14 H3, 13, 7, 14 H3, 13, 7, 14 H3, 10, 7 11 18 12, 12, 23, 12, 13, 14 H3, 10, 7 Keratin 12 NT gl [130786] 107 2 14, 22, 23, 12, 12, 14 Keratin 12 NT gl [130331] 106, 12 116, 13, 12 12, 7 Keratin 13 NT gl [13033	16, 13, 21, 21, 20, 20	12, 6, 13, 7,	Heat shock protein 70	NT, T, M	gi 386785	269, 366, 363	14, 24, 22
22 19 Networksense M eli 705577 45, 70 1, 2 12, 12, 10, 13, 17, 12, 10, 13, 14, 13, 15, 13, 14, 13, 15, 13, 14, 13, 15, 12, 13, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 2, 113, 14, 15, 12, 13, 14, 15, 12, 13, 14, 15, 12, 13, 14, 15, 12, 13, 14, 15, 12, 13, 14, 15, 12, 13, 14, 15, 13, 14, 15, 13, 14, 15, 13, 14, 15, 13, 15, 15, 15, 13, 14, 16, 13, 15, 15, 15, 13, 14, 16, 13, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15		20					
21, 19 5, 9 heterogeneous nuclear ribonudeoprotein H1 NT, T [#] 1503753 46, 57 1, 2, 3 13, 14, 12, 12, 13, 17, 12, 10 64, 12, 15, 14 NT, T [#] 1503753 46, 57 7, 15, 13 13, 19, 10, 13, 14 15, 52, 11, 3 [Hittone H2A NT, M [#] 1503753 442, 300 15, 14 12, 12, 33, 13, 12, 13, 14 15, 52, 11, 3 [Hittone H4A NT, M [#] 1504753 142, 300 155, 14 12, 19, 23, 16, 13, 21, 13, 10 11, 5, 62, 14 [Hittone H4A NT, M [#] 1504533 150, 262, 214 3, 10, 7 12, 19, 23, 16, 13, 21, 13, 10 11, 15, 5 Keratin 1 NT [#] 1307086 107 2 13, 10, 20, 23, 13, 12, 22 10, 19, 16, 30, 21 12, 7 Keratin 12 NT [#] 1307086 107 2 16, 12, 12 12, 7 Keratin 13 NT [#] 150331 151 20 16, 21, 21 12, 7 Keratin 12 NT [#] 150331 164 3 16, 21, 21 12, 7 Keratin 12 NT	22	19	hematological and neurological expressed 1	м	gi 7705877	40	1
12, 21, 20, 13, 71, 21, 20, 6, 1, 21, 2 Histone H2A NT, T, M gl [2111] 247, 486, 216 7, 15, 11 13, 19, 10, 13, 14 15, 5, 11, 11 Histone H2A T, M gl [156855] 442, 300 15, 14 13, 19, 10, 13, 14 15, 5, 21, 11, 11 Histone H4A NT, 16 gl [156857] 442, 300 15, 14 12, 12, 23, 12, 13, 11, 12, 11, 15, Kerstn 1 NT, 16, 16, 14, 14, 15, 17, 18, 17, 12, 11, 15, Kerstn 1 NT, 16, 16, 14, 14, 13, 17, 12, 11, 15, Kerstn 1 NT, 16, 16, 14, 14, 13, 17, 19, 12, 11, 15, Kerstn 1 NT, 16, 16, 12, 12, 11, 12, 11, 15, Kerstn 1 NT, 16, 16, 12, 12, 11, 12, 11, 15, Kerstn 13 NT, 16, 16, 12, 12, 11, 12, 11, 15, Kerstn 13 NT, 16, 11, 12, 11, 12, 11, 13, 14, 13, 12, 11, 13, 14, 12, 11, 13, 14, 12, 11, 12, 11, 12, 11, 12, 11, 12, 11, 12, 11, 12, 11, 13, 14, 12, 11, 12, 12, 13, 14, 12, 12, 12, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14	21, 19	5, 9	heterogeneous nuclear ribonucleoprotein H1	NT, T	gi 5031753	45, 57	1, 2
13. 14. 12 14. 13. 16 17, 18, 10 14. 13. 15 15, 12, 13, 15, 15, 13 Nithow H28 15, 14 T, M pi 156851 442, 300 15, 14 21, 23, 0, 13, 17, 19, 12, 13, 14 11, 5, 6, 21, 14, 15, 6 NT, 10 pi 150851 142, 300 15, 14 21, 23, 0, 13, 17, 19, 12, 13, 14 11, 5, 6, 21, 43, 15, 6 NT, 10, 8 pi 1306543 105, 262, 314 3, 10, 7 21, 23, 21, 21, 21, 22 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 27 10, 13, 15, 12 10, 13, 15, 12 11, 15, 16, 12 11, 15, 16, 12 11, 15, 16, 12 11, 15, 16, 12 11, 15, 16, 12 11, 15, 16, 12 11, 15, 16, 12 11, 15, 16, 13, 12 12, 14, 14, 15 11, 17 11, 15, 16, 13, 12 12, 14, 14, 15 11, 16, 13, 12, 13, 12 12, 14, 14, 15 11, 16, 13, 12 12, 14, 14, 15 11, 16, 13, 12, 13, 12, 14, 14, 14 11, 16, 13, 14, 13, 12, 14, 14, 14 11, 16, 13, 14, 14, 12, 14, 14, 14, 14 11, 17, 16, 11, 14, 14, 14, 14, 14, 14, 14, 14, 14	12, 21, 20, 13, 17, 12, 10,	6, 1, 21, 2,	Histone H2A	NT, T, M	gi 32111	247, 436, 216	7, 15, 11
17, 8, 9 17, 8, 9 15, 14 15, 24, 30, 31, 71, 91, 14, 56, 52, 14, 14, 50, 52, 14, 51, 53, 52, 52, 72 15, 14 16, 17, 18 14, 15, 24, 15, 52, 14, 11, 15, 64, 11, 15, 16, 16, 16, 17, 18, 8, 9 NT, T, M [] [] 1963431 139, 211, 23, 24, 51, 53, 21, 13, 15, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 10, 16, 10, 10, 16, 10, 10, 16, 10, 10, 16, 10, 10, 16, 10, 10, 16, 10, 10, 16, 10, 10, 16, 10, 10, 10, 16, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10	13, 14, 12	14, 4, 13, 16,					
13.19, 10, 12.14 1, 5, 21, 13, Histone H2B T, M gl [1568551 442, 100 15, 14 21.23, 20, 13, 7, 19, 12, 11, 5, 6, 21, Histone H4A NT, T, M gl [1366431 119, 211, 224 5, 9, 7 12, 19, 23, 16, 13, 21, 13, 12, 11, 15, 6, 14 T, 18, 8, 9 NT, T, M gl [1366431 105, 262, 314 3, 10, 7 10, 20, 23, 13, 12, 22 10, 15, 16 10, 15, 16 10, 15, 16 11, 16 107 2 13 11 keratin 10 NT gl [130768 107 2 16 12 keratin 12 NT gl [130308 107 2 16, 12 tkeratin 12 NT gl [130308 107 2 10 16, 12 12, 7 Keratin 15 NT gl [130309 121 10 7 16, 12, 11 12, 7 Keratin 15 NT gl [13031 51, 63 10 10 16 10 10 16 10 10 10 10 16 10 10 10 10 10 10 10 10 10 10 10 10 10		17, 18, 9					
16, 37, 18 16, 37, 18 11, 14 12, 19, 20, 13, 15, 14, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 12, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 11, 15, 15, 12, 11, 12, 12, 15, 15, 12, 11, 12, 12, 12, 15, 15, 12, 11, 12, 12, 12, 12, 12, 12, 12, 12	13, 19, 10, 13, 14	1, 5, 21, 13,	Histone H2B	Т, М	gi 1568551	442, 300	15, 14
21, 23, 01, 31, 71, 91, 21, 11, 56, 521, 91, 56 Nitered HA NT, 7, M gl (3604301 139, 211, 234 5, 9, 7 21, 92, 23, 16, 13, 21, 13, 14, 17, 18, 9, 17, 18, 9, 17, 18, 19, 17, 18, 19, 17, 18, 19, 17, 18, 19, 17, 18, 19, 19, 16 NT, 7, M gl (346434) 105, 262, 314 3, 10, 7 23 10, 20, 23, 13, 12, 23 10, 19, 16 NT gl (345796) 51 2 13, 21 13, 71 keratin 10 NT gl (345796) 51 2 15 12 keratin 12 NT gl (345796) 51 2 13, 21 13, 7 keratin 15 NT gl (345796) 51 2 21 7 keratin 16 NT gl (345796) 50, 0 31, 2 21, 12, 7, 8 keratin 18 NT gl (345796) 50, 0 31, 2 21, 12, 7, 8 keratin 18 NT gl (345776) 163, 32, 0 31, 44 3, 4, 2 16, 13, 21, 12, 21, 12, 12, 12, 12, 12, 12, 12		16, 17, 18					
13.14 2, 4, 13, 16, 17, 18, 8, 8 No. No. No. No. 12, 19, 23, 16, 13, 21, 13, 10, 20, 23, 13, 12, 22 12, 19, 24, 13, 10, 19, 16, 10, 19, 16, 10, 19, 16, 10, 19, 16, 11, 18, 13, 7 NT. gl 134634 105, 262, 114 3, 10, 7 10, 20, 23, 13, 12, 22 11 keratin 10 NT. gl 130036 107 2 16 12 keratin 10 NT. gl 130036 107 2 16, 21 keratin 13 NT. gl 130036 107 7 16, 21 12, 7 keratin 13 NT. gl 130036 107 7 16, 21 12, 7 keratin 15 NT. gl 130031 107 7 16, 21, 21 12, 13 keratin 15 NT. gl 13011 64 3 21, 1 7, 8 keratin 25 T, NT, T gl 130317 51, 44 2 16, 13, 12, 13, 22 12, 19, 12, 12 keratin 25 NT, T gl 130317 51, 44 2 16, 21, 12, 12, 12, 12, 12 keratin 71 T gl 130316 51, 78 </td <td>21, 23, 20, 13, 17, 19, 12,</td> <td>11, 5, 6, 21,</td> <td>Histone H4A</td> <td>NT, T, M</td> <td>gi 4504301</td> <td>139, 211, 234</td> <td>5, 9, 7</td>	21, 23, 20, 13, 17, 19, 12,	11, 5, 6, 21,	Histone H4A	NT, T, M	gi 4504301	139, 211, 234	5, 9, 7
17, 18, 8, 9 17, 18, 8, 9 17, 18, 8, 9 10, 2, 0, 2, 13, 12, 22 10, 19, 15, 16 100, 2, 0, 2, 13, 12, 22 10, 19, 15, 16 100, 2, 0, 2, 13, 12, 22 10, 19, 15, 16 100, 2, 0, 2, 13, 12, 22 10, 19, 15, 16 100, 2, 0, 2, 13, 12, 22 10, 19, 16 100, 2, 0, 2, 13, 12, 22 10, 19, 16 100, 2 2 13 13, 12 13, 12 14, 15, 7 Keratin 12 NT gl 34033 107 2 16 12 Keratin 12 NT gl 34033 157 9 16, 12, 12 12, 7, 8 Keratin 16 NT gl 120581 1007 7 16, 13, 21 12, 7, 8 Keratin 16 NT gl 130311 64 3 21, 12 7 Keratin 18 NT gl 130311 64 3 16, 13, 21, 12, 12, 12, 12, 13 12, 14, 12 Keratin 27 NT gl 130311 64 3 16, 13, 21, 12, 12, 13, 12 12, 14, 12 Keratin 72 NT gl 130311 64 3 16, 13, 12, 12, 13, 12 12, 16, 13, 12<	13, 14	2, 4, 13, 16,				-	
12, 19, 23, 16, 13, 21, 13, 14, 35, 7 NT, T, M gl 1346343 105, 262, 314 3, 10, 7 12, 22, 23, 12, 13, 12, 22 13, 14, 13, 7 NT, T, M gl 1307086 107 2 13, 20, 23, 13, 12, 22 13, 7 Keratin 10 NT gl 307086 107 2 16 11 Keratin 13 NT gl 307086 107 2 16, 21 12, 7 Keratin 13 NT gl 30303 157 9 16, 21 12, 7 Keratin 15 NT gl 125081 107 7 16, 12, 12 12, 7 Keratin 15 NT gl 130303 107 7 16, 12, 12 12, 7 Keratin 15 NT gl 130303 107 7 16, 13, 12, 13, 7 2, 14, 8 Keratin 15 NT gl 130303 228, 147 16, 4 16, 13, 12, 13, 72 12, 2, 7 Keratin 15 NT gl 130313 64 3 16, 12, 12 12, 13, 0 Keratin 5 NT, T gl 1501331		17, 18, 8, 9					
21, 22, 23, 12, 19, 17, 16, 10, 20, 23, 13, 12, 22, 10, 20, 23, 13, 12, 22, 10, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21	12, 19, 23, 16, 13, 21, 13.	12, 11, 1, 5.	Keratin 1	NT, T, M	gi 1346343	105, 262, 314	3, 10, 7
10, 20, 23, 13, 12, 22 10, 19, 16, 7, 18, 13, 7, 8, 20 Image: the second secon	21, 22, 23, 12, 19, 17, 16.	6, 2, 14, 3.					
17. 18. 13. 7, 18. 23 11. 18. keratin 10 NT el 30706 107 2 16 12. 13. 21 13. 7 keratin 12 NT el 457569 51 2 16. 21 12. 7 Keratin 13 NT el 457569 51 2 16. 21 12. 7 Keratin 15 NT el 1203709 171 18 21 7 Keratin 15 NT el 1203709 171 18 21 7 Keratin 15 NT el 1555701 502. 60 31. 2 21. 12 7, 8 keratin 18 T el 30313 225. 147 16. 4 16. 3, 12. 13. 22 12, 2, 18 keratin 27 NT el 30313 25. 147 16. 4 16. 20. 11. 12 12, 2, 6, 18, Keratin 71 NT, T el 30313 25. 52. 8 3. 2 16. 13. 21. 12, 12, 12, 12, 12, 12, 12, 12, 12, 12,	10, 20, 23, 13, 12, 22	10, 19, 16,					
8, 20 NT g[] 20706 107 2 16 12 keratin 12 NT g[] 20706 107 2 13.21 13.7 keratin 12 NT g[] 20706 107 2 16.21 12.7 keratin 13 NT g[] 20706 107 7 16.1 12.7 keratin 16 NT g[] 20706 107 7 16.2.1 12.7.3 keratin 16 NT g[] 20706 100 31.2 21 8 keratin 18 T g[] 30309 281.147 16.4 3 21.2 7.8 keratin 27 NT g[] 20706 51.20 16.2.3 16.2.3 12.2.1 12.4.6 21.14 16.4 3 3.2.2 16.2.3 12.6.2.19 keratin 71 NT g[] 153136 51.75.88 3.2.2 15.3.21 12.1.2.0 10.3 12.9.1.2.6 10.3 12.9.1.2.6 10.3 12.9.1.2.6 10.3 12.9.1.2.6 10.3 12.9.1.1.1.2.1.2.1.2.6		17, 18, 13, 7					
23 11 keratin 10 NT g 4057669 51 2 16 12 keratin 13 NT g 4057669 51 2 16, 21 12, 7 keratin 13 NT g 120301 157 9 16, 21 12, 7 keratin 14 NT g 125031 156 9 16, 21, 21 12, 7 keratin 15 NT g 125031 156 107 7 16, 13, 21 12, 7 keratin 17 NT g 457701 16, 32, 20, 32, 33 156 10 21 8 keratin 19 NT g 457754 16, 32, 10 16, 43, 21 16, 43, 21 16, 43, 21 16, 13, 21, 13, 24 16, 13, 21, 13, 24 16, 13, 21 12, 7 keratin 27 NT g 1363339 127, 60 10, 3 16, 13, 21, 13, 22 13, 21, 13, 20 keratin 79 NT g 1363339 127, 60 13 12, 19, 16, 13, 21, 22, 19, 13, 17, 13, 24 13, 34 18, 78 265, 52, 53 3, 3 265, 52,		8, 20					
16 12 keratin 12 NT 8// (455769) 51 2 13, 21 13, 7 keratin 13 NT 8// (455769) 51 2 16, 21 12, 7 keratin 14 NT 8// (1200370) 101 18 21 7 keratin 15 NT 8// (1200370) 50.8 0.0 16, 21, 21 12, 7, 8 keratin 16 NT 8// (1357701) 50.8 0.1 21 7, 8 keratin 19 T 8// (1303) 281, 147 16, 4 16, 13, 21, 12, 2 12, 19, 18 keratin 27 NT 8// (1303) 281, 147 16, 4 16, 23, 21, 20 12, 6, 13, 7 keratin 72 NT 8// (13033) 27, 58 3, 2, 2 16, 13, 21, 20 12, 6, 13, 7 keratin 71 T 8// (13033) 265, 52, 0 13, 14 9, 2 15, 13, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12	23	11	keratin 10	NT	gi 307086	107	2
13. 21 13. 7 tertin 13 NT gi [14033 157 9 16. 21 12. 7 keratin 15 NT gi [12030709 121 18 21 7 keratin 15 NT gi [12030709 121 18 16. 21. 21 12. 7.8 keratin 16 NT gi [1203011 64 30 21 8 keratin 19 NT gi [30311 64 3 21. 12 7.8 keratin 19 NT gi [30311 64. 4 3 16. 13. 21. 3. 22 12. 2. 19. 18 keratin 25 NT, M gi [12072314 42 2 16. 20. 21. 21. 22. 21. 02. 21. 12. 21. 12. r keratin 25 NT, M gi [12030138 51.76 8. 5 16. 13. 21. 32. 22. 12. 13. 21. 12. 12. keratin 5 NT, M gi [12030138 127. 60 10. 3 2 16. 13. 21. 13. 21. 12. 13. 20 Keratin 71 T gi [1303138 127. 60 3. 2 16. 13. 21. 13. 21. 12. 13. 20 Keratin 79 NT, T gi [130313 255. 52.4, 451 26. 53. 3. 3 21. 15. 61. 32. 11. 32. 12. 5. 6. 2 keratin 8	16	12	keratin 12	NT	gi14557699	51	2
16, 21 12, 7 Kerstin 14 NT gl 12803709 171 18 21 7 Kerstin 15 NT gl 12803709 171 18 16, 21, 21 12, 13, 7 Kerstin 16 NT gl 129581 107 7 16, 13, 21 12, 13, 7 Kerstin 18 NT gl 13031 64 3 21, 21 7, 8 Kerstin 19 NT, T gl 13031 64 3 16, 13, 21, 12, 2 12, 19, 18 Kerstin 12 T, M gl 14039 281, 147 16, 4 16, 21, 12, 2 12, 6, 2, 19, Kerstin 2 NT, T gl 1543134 42 2 16, 13, 21 12, 13, 20 Kerstin 71 NT, T gl 1561399 133, 41 9, 2 16, 13, 21, 12 12, 13, 20 Kerstin 71 NT, T gl 130139 126, 52, 52, 453 26, 33, 2 16, 13, 21, 13, 21, 12, 14, 14, 14, 14 12, 14, 13, 14, 15, 14, 14, 14 14, 14, 14 9, 14 130 133, 14 9, 2 16, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 2	13.21	13.7	keratin 13	NT	gi 34033	157	9
11 7 teratin 15 NT gl [125931 107 7 16, 13, 21 12, 13, 7 keratin 16 NT gl [125931 156 10 16, 21, 21 12, 7, 8 keratin 18 T gl [135931 156 10 21 8 keratin 18 T gl [1459771 16, 43 31, 2 21, 21 7, 8 keratin 25 NT, T gl [1497734 16, 43 32, 20 8, 5 16, 21, 12, 22 12, 6, 13, 7 keratin 25 NT, M gl [1493136 51, 75, 88 3, 2, 2 16, 13, 21, 20 12, 6, 13, 7 keratin 6 NT, M gl [1493136 51, 75, 88 3, 2, 2 16, 13, 21, 20 12, 6, 13, 7 keratin 71 T gl [15013839 127, 60 10, 3 21 20 Keratin 71 NT gl [1397526 86, 66 6, 6, 3 12, 19, 16, 13, 21, 20, 20 6, 13, 20 Keratin 71 NT gl [1397525 86, 57, 57 2, 1 1 1, 3, 7, 8 2	16.21	12.7	Keratin 14	NT	gi 12803709	171	18
16, 13, 21 12, 13, 7 teratin 16 NT gl (1) 195531 156 10 16, 21, 21 12, 7, 8 keratin 17 T gl (3) 331 64 3 21, 21 7, 8 keratin 19 NT, T gl (3) 331 64 3 16, 13, 12, 12, 22 12, 19, 18 keratin 25 T, M gl (3) 331 64 3 16, 23, 12 12, 11, 2 keratin 25 N, T gl (1) 477331 42 2 16, 20, 12, 13, 22 12, 6, 7, 19 keratin 71 NT, T gl (1) 1933131 42 2 16, 13, 21, 20 12, 6, 13, 7 keratin 71 T gl (1) 1503189 133, 41 9, 2 16, 13, 21, 13, 21, 12, 12, 12, 6, 6, 13, 7 keratin 71 T gl (3) 313 265, 524, 451 26, 33, 36 20, 12, 20, 13, 22 19, 13, 17, 18, 7, 18, 78 12, 19, 14, 13, 12, 12, 19, 16, 13, 20 K4 ratin 9 T, M gl (12) 1757428 86, 57, 57 2, 1, 1 21, 19, 16, 13, 20 13, 20 K4 ratin 9 T, M gl (12) 1757428 86,	21	7	keratin 15	NT	gi 125081	107	7
10, 21, 21 12, 7, 8 teratin 17 NT, T g 4557701 502, 80 31, 2 21 8 keratin 18 T g 4557701 502, 80 31, 2 21, 21 7, 8 keratin 19 NT, T g 14039 281, 147 16, 4 16, 13, 12, 13, 22 12, 2, 19, 18 keratin 25 NT, T g 28317 42 2 16, 21 12, 7 keratin 5 NT, T g 28317 42 2 16, 13, 21, 20 12, 6, 19, keratin 5 NT, T g 14733316 42 2 16, 13, 21 21, 13, 20 Keratin 6 NT, T g 15031839 133, 41 9, 2 16, 13, 21 21, 5, 6, 2, keratin 79 NT, T g 13979526 86, 68 6, 3 2 3, 3 2 2, 5, 52, 4, 451 2, 6, 3, 8 2, 2, 2, 5 2, 4 2 1, 3 1, 1, 3, 1, 7, 8 13, 21, 13, 20 13, 17, 7 g 13979526 16, 3, 32 2, 5, 52, 4, 451 26, 53, 36 12, 19, 16, 13, 13, 22 13, 20 Roco	16, 13, 21	12, 13, 7	keratin 16	NT	gi 1195531	156	10
21 8 keratin 18 NT g[13031] 64 3 21, 21 7,8 keratin 18 NT, T g[13031] 64 3 21, 21 7,8 keratin 19 NT, T g[13033] 64 3 16, 31, 22 12, 21, 91, 81 keratin 25 NT, T g[128317] 51, 146 2 11 16, 21 12, 7 keratin 72 NT g[128317] 42 2 16, 13, 21, 20 12, 6, 13, 7 keratin 6 NT, T g[1503183] 127, 60 10, 3 16, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 21, 13, 74, 18, 78 keratin 71 T g[130313] 226, 524, 451 26, 33, 36 23, 16, 22, 12, 13 12, 21, 2, 21, 13, 2	16, 21, 21	12 7 8	keratin 17	NTT	gi 4557701	502 80	31.2
Description Description NT, T gl 34029 281, 147 16, 24 16, 13, 12, 13, 12 12, 11, 2 keratin 19 T, M gl 34029 281, 147 16, 24, 24 16, 21 12, 7 18, 84 Keratin 25 NT, T gl 34029 281, 147 16, 24, 24 16, 21 12, 7 keratin 25 NT, T gl 34029 281, 144 42 2 16, 21, 13, 22 12, 6, 13, 7 keratin 6 NT, T gl 1543136 51, 75, 88 3, 2, 2 16, 13, 21, 20 12, 6, 13, 7 keratin 6 NT, T gl 3031389 127, 60 10, 3 16, 13, 21, 12, 21, 18, 20 keratin 79 NT, T, M gl 30313 265, 524, 451 26, 33, 36 20, 12, 20, 13, 22 19, 13, 17, 13, 12, 12, 20, 20 6, 13, 20 keratin 9 T, M gl 30313 265, 524, 451 26, 33, 36 22 19 POEA associated protein NT, T, M gl 30431 265, 524, 451 26, 33, 36 13 18 peptide chain release factor 3 M <td>21</td> <td>8</td> <td>keratin 18</td> <td>т</td> <td>gi 30311</td> <td>64</td> <td>3</td>	21	8	keratin 18	т	gi 30311	64	3
International sector in the sector	21 21	7.8	keratin 19	NTT	gi 34039	281 147	16.4
International structure International structure <thinternational structure<="" th=""> <thinternational st<="" td=""><td>16 13 12 13 22</td><td>12 2 19 18</td><td>keratin 2</td><td>тм</td><td>gi 547754</td><td>163, 230</td><td>8 5</td></thinternational></thinternational>	16 13 12 13 22	12 2 19 18	keratin 2	тм	gi 547754	163, 230	8 5
16:21 12:7 Reatin 27 Num 17:7	16, 23, 12, 13, 12	12, 12, 13, 10	keratin 25	NT T	gi 28317	51 146	2 11
Internal	16,23,12	12 7	keratin 27	NT	gi 74723314	42	2
Abs, B., B., B., B., Barbart, S., Barbart, S., Barbart, S., B., B., B., B., B., B., B., B., B., B	16 20 12 13 22	12 6 2 19	keratin 4	NTTM	gi 15431316	51 75 88	322
16, 13, 21, 20 12, 6, 13, 7 keratin 5 NT, M gl 18999435 133, 41 9, 2 16, 13, 21 12, 13, 20 Keratin 71 T gl 15618995 53 2 16, 21, 13 12, 18, 20 Keratin 71 T gl 35618995 53 2 16, 21, 21, 21, 21, 21, 21, 21, 21, 25, 6, 2, 19, 13, 17, 18, 7, 8 Keratin 9 NT, T, M gl 30313 265, 524, 451 26, 33, 36 22, 16, 22, 12, 13 12, 12, 1, 21, 18, 7, 8 KM-HN-1 protein NT, T, M gl 3686856 60, 83, 257 2, 1, 1 18, 32, 12, 02, 20 6, 13, 20 KM-HN-1 protein NT, T, M gl 17986258 106 5 21 8 Myosin light chain 6 NT gl 17986258 108 5 22 19 PDGFA associated protein 1 M gl 17926278 12 1 21 8, 9 phospholipase Calpha NT gl 303618 82 4 12 2 predicted similar to hCG1643231 T gl 150518829 7, 4 1	10, 10, 11, 10, 11	18		, .,	81113431310	51, 75, 00	3, 2, 2
Note 1 = 1, 2 Note 1 =	16 13 21 20	12 6 13 7	keratin 5	NT M	gi 18999435	133 41	9.2
11 20 Keratin 71 Kir, T gil 15618995 33 20 11, 12, 13, 11, 12, 12, 12, 12, 12, 12, 12, 13, 13, 14, 15, 6, 2, Keratin 8 NT, T, M gil 39313 265, 524, 451 26, 33, 36 20, 12, 20, 13, 22, 14, 32, 1, 34, 17, 18, 7, 8 12, 11, 21, 18, 7, 8 13, 13, 21, 20, 20 6, 13, 20 KM-HN-1 protein NT, T, M gil 12157428 86, 57, 57 2, 1, 1, 1 21, 19, 16, 13, 13, 22 12, 5, 19, 18 Iamin a NT, T, M gil 1296528 108 5 22 19 POGFA associated protein 1 M gil 1296528 108 5 21 8 Myosin light chain 6 NT gil 1306585 60, 83, 257 2, 2, 6 21 8 popt Associated protein 1 M gil 126018829 75 2 13 18 peptide chain release factor 3 M gil 16018829 75 2 14 12 2 predicted similar to hCG1643231 T gil 16018829 75 2 15, 20 12, 6 replictation protein A3	16, 13, 21, 20	12, 13, 20	Keratin 6	NT T	gil 5031839	127 60	10.3
Info. 21, 13 12, 19, 20 Keratin 79 NT, T Il 2199, 229 86, 68 6, 3 12, 19, 13, 21, 13, 21, 12, 12, 12, 13, 17, 18, 7, 8 12, 19, 13, 17, 18, 7, 8 Il 2193, 17, 18, 7, 8 Il 23, 19, 212, 12, 12, 12, 12, 12, 12, 12, 12, 1	21	20	Keratin 71	т	gi 15618995	53	20, 5
12, 19, 16, 13, 21, 12, 12, 5, 6, 2 keratin 8 NT, T, M gi [30313] 265, 524, 451 28, 3, 36 20, 12, 20, 13, 22 19, 13, 17, 14 gi [30313] 265, 524, 451 28, 3, 36 23, 16, 22, 12, 13 12, 12, 12, 19, 18, 17, 14 12, 12, 19, 16, 13, 13, 22 12, 51, 12, 19, 18, 1amin a NT, T, M gi [30313] 265, 57, 57 2, 1, 1 21, 19, 16, 13, 13, 22 12, 5, 19, 18, 1amin a NT, T, M gi [1786258] 108 5 22 19 POGFA associated protein 1 M gi [1786258] 108 5 21 8 Myosin light chain 6 NT gi [30318] 82 4 13 18 peptide chain release factor 3 M gi [1702475 42 1 13 18 peptide chain release factor 3 M gi [160168829 75 2 14 12 2 predicted similar to hCG1643231 T gi [30226 50 4 1 15, 20 12, 6 replication protein A3 NT, T gi [405687 61, 42 4, 1 16 12 Rho GTPase activating protein 23	16 21 13	12 18 20	Keratin 79	NTT	gi 39795269	86 68	6.3
12. 10. 13. 22 19. 13. 17. 18. 7.8 19. 13. 17. 18. 7.8 10. 12. 0. 13. 22 19. 13. 17. 13. 21. 0. 13. 22 19. 13. 17. 18. 7.8 read to the second sec	12 19 16 13 21 13 21	12 5 6 2	keratin 8	NTTM	gi 30313	265 524 451	26 33 36
List, etc. Bit. List, 21, 3 List, 7, 8 List, 7, 8 List, 7, 8 23, 16, 22, 12, 13 12, 11, 2, 19 18 T, M gi 453155 56, 55 3, 3 13, 21, 20, 20 6, 13, 20 8, 9 NT, T, M gi 21757428 86, 57, 57 2, 1, 1 21, 19, 16, 13, 13, 22 12, 5, 19, 18, 1amin a NT, T, M gi 368656 60, 83, 257 2, 2, 6 22 19 POGFA associated protein 1 M gi 702475 42 1 13 18 peptide chain release factor 3 M gi 702475 42 1 21 8, 9 predicted similar to hCG1643231 T gi 303618 82 4 12 2 predicted similar to hCG1643231 T gi 150488 67, 40 1, 2 13, 21 13, 20 ProSAPIP1 protein T, M gi 150488 67, 40 1, 2 14, 12 12 fer plication protein A3 NT, T gi 1606587 61, 42 4, 1 13, 21 13, 20 FoSAPIP1 protein	20 12 20 13 22	19 13 17		, .,	81130313	200, 024, 401	20, 33, 30
12, 15, 12, 13 12, 11, 2, 19 keratin 9 T, M gl 453155 56, 55 3, 3 13, 21, 20, 20 6, 13, 20 KM-HN-1 protein NT, T, M gl 21757428 86, 57, 57 2, 1, 1 21, 19, 16, 13, 13, 22 12, 5, 19, 18, lamin a NT, T, M gl 368856 60, 83, 257 2, 2, 6 21 8 Myosin light chain 6 NT gl 17986258 108 5 22 19 PD6FA associated protein 1 M gl 7657441 85 2 21 8, 9 phospholipase Calpha NT gl 30618 82 4 12 2 predicted similar to hCG1643211 T gl 16916829 75 2 19 5 progerin T gl 30518 60, 40, 1, 2 4 12 12, 6 proteome inhibitor hPl31 T, M gl 1505488 67, 40 1, 2 15, 20 12, 6 rebosmal protein 32 NT gl 149489236 154 5 17 4 ribosmal pro	20, 12, 20, 13, 22	19, 13, 17,					
L2, L2, L2, L2, L2, L3, L4, L4, L4, L4, L4, L4, L4, L4, L4, L4	22 16 22 12 12	12 11 2 10	keratin 9	тм	ai1452155	56 55	3 3
13, 21, 20, 20 6, 13, 20 KM-HN-1 protein NT, T, M gl 21757428 86, 57, 57 2, 1, 1 21, 19, 16, 13, 13, 22 12, 5, 19, 18 lamin a NT, T, M gl 386556 60, 83, 257 2, 2, 6 21 8 Myosin light chain 6 NT gl 13966258 1008 5 21 8 popt6A associated protein 1 M gl 757474 85 2 13 18 peptide chain release factor 3 M gl 30613 82 4 12 2 predicted similar to RCG1643231 T gl 30518 82 4 12 2 predicted similar to RCG1643231 T gl 405168829 75 2 13 13, 20 PosRPIP protein T, T gl 405644 2, 3 2 14 10 proteasome inhibitor hP131 T, M gl 405687 61, 42 4, 1 16 12 Rho GTase activating protein 23 NT gl 4056957 61, 42 4, 5 11 15 <td>23, 10, 22, 12, 13</td> <td>18</td> <td>ACIACITY S</td> <td>1, 1</td> <td>P11422222</td> <td>50, 55</td> <td>J, J</td>	23, 10, 22, 12, 13	18	ACIACITY S	1, 1	P11422222	50, 55	J, J
21, 19, 16, 13, 13, 22 12, 5, 19, 18, 18 min a NT, T, M gl 186556 60, 83, 257 2, 2, 6 21 8 Myosin light chain 6 NT, T, M gl 198656 60, 83, 257 2, 2, 6 21 8 Myosin light chain 6 NT gl 17996253 108 5 22 19 PDGFA associated protein 1 M gl 7/57441 85 2 13 18 peptide chain release factor 3 M gl 7/62176 42 1 12 2 predicted similar to hC01642331 T gl 1303618 62 4 12 2 predicted similar to hC01642331 T gl 1303618 62 4 13, 21 13, 20 ProSAPIP1 protein T, T gl 130518 62 4 14, 21 12 protessome inhibitor hP131 T, M gl 1565548 67, 40 1, 2 15, 20 12, 6 replication protein 32 NT, T gl 14506597 61, 42 4, 1 16 12 RN G GTAses citvating p	13, 21, 20, 20	6.13.20	KM-HN-1 protein	NT. T M	gi 21757429	86. 57 57	2.1.1
Arr, F. L. P. J. S. P. K. Hammer Maximum Sector	21, 19, 16, 13, 13, 22	12. 5. 19. 19	lamin a	NT. T M	gi 386856	60, 83, 257	2, 2, 6
0.7. Myosin light chain 6 NT gl 17986258 108 5 22 19 PDGFA associated protein 1 M gl 7657441 85 2 13 18 peptide chain release factor 3 M gl 7657441 85 2 21 8,9 phospholipase Calpha NT gl 16016829 75 2 19 5 progerin T gl 30618 82 4 12 2 predicted similar to hCG1643231 T gl 16616829 75 2 19 5 progerin T gl 30618 67,40 1,2 16,20 12,6 replication protein A3 NT, T gl 4506597 61,42 4,1 16 12 Rho GTPase activating protein 23 NT gl 1988236 154 45 17 4 ribosomal protein 521 T gl 4506597 61,42 4,1 12 15 smail nuclear ribonucleoprotein polypetide D3 T gl 4506594		8 9		, 1, 191	P.120020	···, ···, <u>···</u>	~, <i>2</i> , V
1 0 Information of the second protein 1 Information of the secon	21	8	Myosin light chain 6	NT	gi 17986259	108	5
La Described protein process m </td <td>22</td> <td>19</td> <td>PDGFA associated protein 1</td> <td>м</td> <td>gi 7657441</td> <td>85</td> <td>2</td>	22	19	PDGFA associated protein 1	м	gi 7657441	85	2
21 25 26 27 27 27 27 27 27 27 27 28 27 2 19 5 progetin T gl [303618 82 4 13 21 2 predicted similar to hCG1643231 T gl [31228 90 4 13 21 13.20 ProSAPP1 protein NT, T gl [31228 90 4 16 proteasome inhibitor hP131 T, M gl [3156438 67, 40 1, 2 16 12 Rho GTPase activating protein 23 NT gl [1455488 67, 40 1, 2 17 4 ribosomal protein 33 NT, T gl [14564374] 44 4, 1 12 15 Ribo GTPase activating protein 23 NT gl [14564374] 42 4 12 15 Ribo Gmal protein 519 NT, T gl [14504594 42 4 12 15 RNB inding motif protein, X-linked T gl [1939326 154 5	12	19	nentide chain release factor 2	D.4	gi 702247F	42	1
L2 0, J prinziprior para Compris ministration of the comparation of the	21	8.9	nhosnholinase Galnha	NT	gil 303619	82	4
12 12 13 13 14 15 16 17 16 17 16 17 16 17 17 18 13 13 20 20 6 18 21 13 20 20 6 17 18 17 18 17 18 17 17 17 18 17 18 17 18 17 18 17 18 17 18 17 18 19 12 15 17 18 19 17 18 19 17 19 14 14 1 1 12 15 81 16 12 81 10 12 15 14 4 5 19 5 RPB5 T 8 114 16 12 4 5 12 12 15 smail nuclear ribonucleoprotein polypetide D3 T 8 14 4 5 12	12	2	predicted similar to hCG1643231	т	gi 169168220	75	2
1.2. 1.3.20 Probability protein 1.7. Figure 1942.83 900 4 13.21 13.20 ProSAPIP1 protein NT, T Bi 1762.176 41, 48 2.3 20.20 6 protessome inhibitor hPl31 T, M Bi 17652.176 41, 48 2.3 16.20 12.6 replication protein A3 NT, T Bi 1655488 67, 40 1.2 16 12 Rho GTPase activating protein 23 NT Bi 1955588 61, 42 2 21.12 15. rbiosomal protein s19 NT, T Bi 14566897 41, 45 4, 5 17 4 ribosomal protein s21 T Bi 194389236 154 5 19 5 RPB5 T Bi 194389236 154 5 12 15 small nuclear ribonucleoprotein polypeptide D3 T Bi 194389236 47 1 16 12 thioredoxin prexuidase T Bi 14563589 57 2 2 21. 7 transformation en	19	5	progerin	т	gi 34228	90	4
Addition Production Productio	12 21	12 20	ProSADID1 protein	NT T	gi 54228	41 49	2 2
Loc 20 Docessing multiplication protein h34 I, m Is (i 405687 6i, 4.2 4.1 16 12 Rho GTPase activating protein 23 NT Is (i 405687 6i, 4.2 2 21, 12 15.8 ribosomal protein 39 NT, T Is (i 4506697 6i, 4.2 2 17 4 ribosomal protein 19 NT, T Is (i 4506699 41 1 12 15 RNA binding motif protein, X-linked T Is (i 194389236 154 5 19 5 RPB5 T Is (i 1606912 40 1 12 15 small nuclear ribonucleoprotein polypeptide D3 T Is (i 1547892 40 1 16 12 thioredoxin peroxidase T Is (i 15435349 57 2 21 7, p transformation ergulated nuclear protein NT, T Is (i 4006989 41, 83 1, 2 21 9 tRNA methytransferase 11-2 T Is (i 40089682 50 1 12 13 tubiquinol	20, 20	6	proteasome inhibitor hPI21	T M	gi 1655499	67 40	1 2
12.0 12.0 representation protein 23 NT 8 [17959263 42 2 21,12 15.8 ribosomal protein 19 NT 8 [17959263 42 2 17 4 ribosomal protein 19 NT 8 [17959263 42 2 17 4 ribosomal protein 19 NT 8 [17959263 42 2 17 4 ribosomal protein 19 NT 8 [17959263 42 2 17 4 ribosomal protein 51 T 8 [1406691 41 1 12 15 RNA binding motif protein, X-linked T 8 [1406912 40 1 17,17 3 serpin 85 T 8 [1406912 40 1 12 15 small nuclear ribonucleoprotein polypeptide D3 T 8 [1435579 57 2 21 7 transformation upregulated nuclear protein NT 8 [1345057 42 1 21,21 7,9 transformation upregulated nuclear protein NT	16.20	12.6	replication protein A3	NT T	gi 4506597	61 42	4 1
12 12 12 13 10 017325203 11 117 42 2 17 4 ribosomal protein s21 T gi [14164 47, 145 4, 5 12 15 RNA binding motif protein, X-linked T gi [194389236 154 5 19 5 RP85 T gi [1060912 40 1 17, 17 3 serpin B5 T gi [19439236 80, 114 4, 5 12 15 smail nuclear ribonucleoprotein polypeptide D3 T gi [1543536 97 2 16 12 thioredoxin peroxidase T gi [345057 42 1 21. 7 transformation related protein 14 NT gi [345057 42 1 21. 7 transformation enclead protein 14 NT gi [345057 42 1 21. 7 transformation enclead protein 14 NT gi [3405057 42 1 21. 7 transformation calce prote	16, 20	12,0	Rho GTPase activating protein 22	NT	gi 7950262	42	7, 1
Line Line Housing protein LLS High 1 Big 142.06 47, 1493 43, 14 12 15 RNA binding motif protein, X-linked T gi [194.069 41 1 12 15 RNA binding motif protein, X-linked T gi [194.069 44 1 19 5 RP05 T gi [194.089 40 1 17, 17 3 serpin B5 NT, T gi [194.089 80, 114 4, 5 12 15 small nuclear ribonucleoprotein polypeptide D3 T gi [4579.160 47 1 16 12 transformation related protein 14 NT gi [33415057 42 1 21 7 transformation upregulated nuclear protein NT, T gi [400789 41, 83 1, 2 21 9 tRNA methytrans fersase 11-2 T gi [40035862 50 1 21 8 tumor protein D52-like NT gi [40035862 50 1 12 13, 20, 13 6, 21, 71.80 <td>21 12</td> <td>15.9</td> <td>ribosomal protein s19</td> <td>NTT</td> <td>gi 14164</td> <td>47 145</td> <td>4 5</td>	21 12	15.9	ribosomal protein s19	NTT	gi 14164	47 145	4 5
12 14 16 16 16 16 16 14 1 12 15 RNA binding motifi protein, X-linked T gi 194389236 154 5 19 5 RP85 T gi 194389236 154 5 17 7 3 serpin 85 NT, T gi 379389236 144 4.5 12 15 small nuclear ribonucleoprotein polypeptide D3 T gi 4759160 47 1 16 12 thioredoxin peroxidase T gi 3415057 42 1 21.1 7, 9 transformation upregulated nuclear protein NT, T gi 407089 41, 83 1, 2 21.2 9 tRNA methyltransferase 11-2 T gi 7070477 81 6 21 8 tumor protein D52-like NT gi 40805662 50 1 17 3 ubiquinol-cytochrome credutase core 1 protein T gi 4026054 50 1 12 13, 2,0, 13	17	13,0	ribosomal protein s21	т	gi 4506600	47, 145	1
12 13 Interview protein particle protein particle 1 19/19/393223 154 5 19 5 RPB5 T gl 1606912 40 1 17,17 3 serpin 85 NT, T gl 19/19/39223 40 1 12 15 small nuclear ribonucleoprotein polypeptide D3 T gl 19/19/3024 40 1 16 12 thioredoxin peroxidase T gl 16/3534 57 2 21 7 transformation related protein 14 NT gl 3/3415957 42 1 21, 21 7,9 transformation upregulated nuclear protein T gl 1400789 41,83 1,2 21 9 tRNA methytransferase 11-2 T T gl 1400789 41,83 1,2 21 8 tumprotein D52/1ke NT gl 40078962 50 1 17 3 ublquinol-cytochrome creductase core 1 protein T gl 19/15634 88 2 12, 13, 20, 13 6, 2, 17, 18	17	4	RNA binding motif protein V linked	T	gi 14300099	41	1
12. 3 1 8 1000912 400 1 17, 17 3 serpin 85 r r g 1400912 400 1 12 15 small nuclear ribonucleoprotein polypeptide D3 T g 14759160 47 1 16 12 thioredoxin peroxidae T g 14759160 47 1 21 7 transformation related protein 14 NT g 134315057 42 1 21, 21 7,9 transformation upregulated nuclear protein NT, T g 1400824 1,83 1,2 21 9 tRNA methytransferase 11-2 T g 1705477 81 6 21 8 tumor protein D52-like NT g 140083862 50 1 12, 13, 20, 13 6, 2, 17, 18 bilguitini tubiquitor/stafe core 1 protein T g 14929609 38 1 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT g 4929609 38 1	12	12	PDRS	T	gi 1060013	104	5
Ar, Ar 3 Serpin DS NI, 1 B() 114 4, 5 12 15 small nuclear ribonucleoprotein polypeptide D3 T gi 475926 80, 114 4, 5 16 12 thioredoxin peroxidase T gi 475926 87, 12 1 21 7 transformation related protein 14 NT gi 345935 97 2 21, 21 7, 9 transformation related protein 14 NT gi 345057 42 1 21, 21 7, 9 transformation cupregulated nuclear protein NT, T gi 4007897 41, 83 1, 2 21 8 tumor protein DS2-like NT gi 4008682 50 1 17 3 ubiquinol-cytochrome creducase core 1 protein T gi 4008682 50 1 12, 13, 20, 13 6, 2, 17, 18 Ubiquitin Trail and therein 1, 17 3 ubiquitin carboxyl-terminal hydrolase L5 NT gi 4929609 38 1 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT </td <td>17 17</td> <td>2</td> <td>seroin R5</td> <td>NT T</td> <td>gi 1000912</td> <td>90 114</td> <td>1</td>	17 17	2	seroin R5	NT T	gi 1000912	90 114	1
12 13 smart notice protein polypeptide US 1 g 4735260 47 1 16 12 thioredrain neuroscient polypeptide US T g 543539 57 2 21 7 transformation related protein 14 NT g 3415057 42 1 21.21 7.9 transformation upregulated nuclear protein NT, T g 7005477 81 6 21. 9 tRNA methyltransferase 1:-2 T g 7005477 81 6 21. 8 tumor protein D52-like NT g 40005862 50 1 17 3 ubiquinol-cytochrome c reductase core 1 protein T g 40005862 50 1 12, 13, 20, 13 6, 2, 17, 18 Ubiquitin T// M g 229532 48, 62 3, 3 16 12 ubiquitin carboxyl-terminal hydrolase US NT g 4929609 38 1	12	3	serpin 05	т, г	gi 4750160	00, 114 A7	4, 5
Lo L2 Inforeoxin peroxidase I B 19453549 57 2 21 7 transformation related protein 14 NT ej 33415057 42 1 21, 21 7,9 transformation upregulated nuclear protein NT ej 33415057 42 1 21, 21 9 tRNA methyltransferase 11-2 T gi 705477 81 6 21 8 tumor protein D52/like NT gi 4005662 50 1 17 3 ubiquinol-cytochrome credutase core 1 protein T gi 4005662 50 1 12, 13, 20, 13 6, 2, 17, 18 Ubiquitin Trote 1 T gi 4025602 48, 62 3, 3 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT gi 4929609 38 1	12	15	sman nuclear ribonucleoprotein polypeptide D3		gi 4759160	4/	1
24 7 transformation related protein 14 NI 8[13451057 42 1 21, 21 7,9 transformation upregulated nuclear protein NT, T 8[145059 41, 83 1, 2 21 9 tRNA methyltransferase 11-2 T gi [4705477 81 6 21 8 tumor protein D52-like NT gi [40005862 50 1 17 3 ubiquino1-cytochrome creductase core 1 protein T gi [3151634 88 2 12,13,20,13 6,2,17,18 Ubiquitin T,M gi [25932 48,62 3,3 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT gi [4029609 38 1	10	12	transformation related proto-in 44	NT	gi 5453549	5/	2
CL, 21 7,9 transformation upregulated nuclear protein Ni, 1 gl (140/28) 41, 83 1, 2 21 9 tRNA methyltransferase 11-2 T gl (705477 81 6 21 8 tumor protein D52-like NT gl (400/28) 50 1 17 3 ubiquinol-cytochrome creductase core 1 protein T gl (3005862 50 1 12, 13, 20, 13 6, 2, 17, 18 Ubiquitini T, M gl (229532 48, 62 3, 3 16 12 ubiquitin carboxyl-terminal hydrolase US NT gl (4929609) 38 1	21	7.0	transformation related protein 14	NT T	gi 33415057	42	1
21 9 ttmm methytransterase 11-2 T 8 40005862 50 1 21 8 tumor protein D52-like NT eil 40005862 50 1 17 3 ubiquinol-cytochrome c reductase core 1 protein T gi 40005862 50 1 12, 13, 20, 13 6, 2, 17, 18 Ubiquitin T mit second 1 and	21, 21	7,9	transformation upregulated nuclear protein	NĨ, T	gi 460789	41, 83	1, 2
C1 8 Lumor protein US2-IKRE NT gl 40805862 50 1 17 3 ubiquinol-cytochrome creductase core 1 protein T gl 5654 88 2 12, 13, 20, 13 6, 2, 17, 18 Ubiquitin T, M gl 229532 48, 62 3, 3 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT gl 4292609 38 1	21	9	trina methyltransferase 11-2	r .	gi //05477	81	6
17 3 Ubiquinoi-cyconrome c reautase core 1 protein T 8 2 12,13,20,13 6,2,17,18 Ubiquitin T, M 8 2 3,3 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT gl [229532 48,62 3,3 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT gl [4929609 38 1	21	8	tumor protein D52-like	NT	gi 40805862	50	1
12, 15, 20, 13 0, 2, 17, 18 UDiquitin I, M gi 229532 48, 62 3, 3 16 12 ubiquitin carboxyl-terminal hydrolase L5 NT gi 4929609 38 1	1/	5	ubiquinoi-cytochrome c reductase core 1 protein	T 14	gi 515634	88	2
10 12 judiquitin carboxyi-terminal nyoroisse LS NI gi j4929609 38 1	12, 13, 20, 13	0, 2, 17, 18	ubiquitin	1, M	gi 229532	48, 62	3, 3
Bod-NT Disch-T Disch-T	16	12	ubiquitin carboxyl-terminal hydrolase L5	NT	gi 4929609	38	1

J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2013 April 15.